ClinicalTrials.gg
Not yet recruitingNCT07153835Updated Sep 4, 2025

Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study

A Phase 4 interventional study of Paliperidone extended-release (ER) in Schizophrenia, sponsored by Sher-E-Bangla Medical College. Not yet recruiting at 1 site in Bangladesh. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Sher-E-Bangla Medical College · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
505
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Planned enrollment
17th of 115
505 · median 178
Started
2025
with 1 other
Phase 4
42 of 115
5 open now
Registered
112th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 17th largest by planned enrollment, is one of 2 that started in 2025, is one of 42 in phase 4, and was the 112th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, prospective quasi-experimental study evaluating the efficacy and safety of extended-release paliperidone in adults with schizophrenia in Bangladesh. The study will assess psychotic symptom improvement using the PANSS scale, monitor side effects using GASS, and evaluate quality of life via WHOQOL-BREF.

Read the detailed description

Despite global evidence supporting the effectiveness of paliperidone, there is limited data from low- and middle-income countries such as Bangladesh. This study addresses this evidence gap by assessing the efficacy and safety of paliperidone ER in a real-world, multi-site setting. The primary endpoint is the change in PANSS score after 12 weeks of treatment. Secondary outcomes include side-effect profile, safety assessments, and quality of life. A total of 505 participants will be enrolled.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone
  • Extended-Release Paliperidone
  • Second-Generation Antipsychotics
  • PANSS
  • GASS
  • WHOQOL-BREF
  • Quasi-Experimental Study
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years
  • Diagnosed with schizophrenia according to criteria
  • At least 3 months since the initial diagnosis of schizophrenia
  • Either antipsychotic-naïve or previously treated with one antipsychotic but requiring a change due to non-response, poor response, or intolerable side effects. (If previously treated, a of 7 days before study medication initiation)
  • PANSS (Positive and Negative Syndrome Scale) total score ≥70
  • Clinically stable for at least 2 weeks before enrollment

Exclusion criteria

Exclusion Criteria:

  • History of being diagnosed with treatment-resistant schizophrenia
  • Comorbid severe medical or neurological conditions
  • Pregnant or lactating women
  • Previous known to paliperidone or risperidone
  • Use of long-acting injectable antipsychotics within the last 3 months
  • Current diagnosis of substance related disorder or substance misuse in the previous month
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
505 participants (estimated)

Study arms

  • Experimental
    Paliperidone Extended-Release Treatment Arm

    Participants in this arm will receive paliperidone extended-release (ER) tablets at a flexible daily dose of 6-12 mg, as determined by the treating psychiatrist based on clinical judgment. The treatment will continue for 12 weeks, with clinical assessments at baseline, 6 weeks, and 12 weeks to evaluate efficacy, safety, and quality of life.

    Drug: Paliperidone extended-release (ER)

Interventions

  • DrugPaliperidoneStudies of PaliperidonePaliperidone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Paliperidone extended-release (ER) tablets will be administered orally once daily at flexible doses ranging from 6 mg to 12 mg, based on the clinical judgment of the treating psychiatrist. The treatment duration is 12 weeks. Dose adjustments may be made throughout the study period depending on patient response and tolerability.

06

What researchers measure

Primary outcomes

  1. Change in PANSS total score from baseline to 12 weeks

    The Positive and Negative Syndrome Scale (PANSS) will be used to assess the severity of schizophrenia symptoms. The total score ranges from 30 to 210, with higher scores indicating more severe symptoms. The primary outcome is the change in total PANSS score from baseline to week 12 following treatment with paliperidone extended-release.

    Time frame: Baseline, Week 6, Week 12

Secondary outcomes

  1. Assessment of Side Effects Using GASS Score

    The Glasgow Antipsychotic Side-Effect Scale (GASS) will be used to assess self-reported side effects of paliperidone. For participants who are not literate or have difficulty completing the form independently, a trained psychiatrist will administer the scale in an interview format.

    Time frame: Baseline, Week 6, and Week 12

  2. Changes in Quality of Life Measured by WHOQOL-BREF

    The WHO Quality of Life-BREF (WHOQOL-BREF) will be used to assess quality of life across four domains: physical health, psychological health, social relationships, and environment. For participants who are not literate, the questionnaire will be administered by a trained psychiatrist through structured interviews.

    Time frame: Baseline and Week 12

Other outcomes

  1. Changes in Laboratory Parameters and ECG

    Safety will be assessed through laboratory investigations including complete blood count, liver and renal function tests, fasting glucose, and lipid profile, as well as 12-lead ECG. Abnormal values or clinically significant changes from baseline will be recorded.

    Time frame: Baseline and Week 12

  2. Change in Body Mass Index (BMI)

    BMI will be calculated as weight (kg) divided by height squared (m²). Height will be measured once at Baseline (without shoes, using a stadiometer) and used for all BMI calculations. Weight will be measured at each visit on a calibrated digital scale with participants in light clothing and no shoes. The reported outcome will be BMI (kg/m²) at each time point and the change from Baseline. Weight and height are collected only to compute BMI and will not be reported as separate outcomes.

    Time frame: Baseline, Week 6, and Week 12

07

Study locations

1 site
  • Sher-E-Bangla Medical College Hospital
    Barishal, 8200, Bangladesh
    • Mohammad Tariqul Alam Principal Investigator, FCPS · Contactsum.tariq@gmail.com · +8801818222228
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) may not be shared publicly, as the decision to share lies with the trial sponsor, ACI Pharmaceuticals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Mar 2026, 6 months later.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 6 months is below that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2025
First posted
Sep 4, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153835
Lead sponsor
Sher-E-Bangla Medical College
Collaborators
ACI Pharmaceuticals, US-Bangla Medical College Hospital, Dr. M M Jalal Uddin, Dr.Ahsan Aziz Sarkar
Responsible party
Mohammad Tariqul Alam (Professor, Sher-E-Bangla Medical College) — Principal investigator
First posted
Sep 4, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Sep 4, 2025

Study contacts

Mohammad Tariqul Alam Principal Investigator, MBBS, FCPS (Psychiatry)
Contact
sum.tariq@gmail.com
+8801818222228
Dr. Ahsan Aziz Sarkar Co-investigator, MBBS, FCPS (Psychiatry)
Contact
ahsan.psychiatry@gmail.com
+8802588846231
Dr. M M Jalal Uddin Co-invetigator, MBBS,FCPS (Psychiatry), MPH
study director · National Institute of Neurosciences and Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion